Manatuck Hill Partners LLC Makes New $3.60 Million Investment in AngioDynamics, Inc. $ANGO

Manatuck Hill Partners LLC acquired a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 276,500 shares of the medical instruments supplier’s stock, valued at approximately $3,597,000. AngioDynamics accounts for approximately 1.2% of Manatuck Hill Partners LLC’s investment portfolio, making the stock its 28th biggest position.

Other large investors have also modified their holdings of the company. BlackRock Inc. acquired a new position in AngioDynamics in the second quarter worth about $49,480,000. Kotler Kevin acquired a new stake in AngioDynamics during the fourth quarter valued at approximately $21,997,000. Weber Capital Management LLC ADV acquired a new stake in AngioDynamics during the second quarter valued at approximately $17,649,392,000. Paradigm Capital Management Inc. NY bought a new stake in shares of AngioDynamics in the 2nd quarter valued at approximately $8,732,000. Finally, UBS Group AG raised its holdings in shares of AngioDynamics by 83.6% in the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after buying an additional 501,881 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Price Performance

Shares of ANGO opened at $15.95 on Wednesday. The company has a market capitalization of $659.21 million, a P/E ratio of -18.33 and a beta of 0.33. AngioDynamics, Inc. has a one year low of $9.39 and a one year high of $16.29. The business’s 50 day simple moving average is $14.11 and its 200-day simple moving average is $12.14.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The firm had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, sell-side analysts anticipate that AngioDynamics, Inc. will post -0.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ANGO. Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Canaccord Genuity Group increased their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. HC Wainwright lifted their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, AngioDynamics has a consensus rating of “Hold” and a consensus target price of $19.50.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 6.00% of the company’s stock.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.